Haem arginate - Orphan Europe

Drug Profile

Haem arginate - Orphan Europe

Alternative Names: Hemin - Orphan Europe; Normosang

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Orphan Europe
  • Developer CMIC; Orphan Europe
  • Class Antibacterials; Antineoplastics; Haemes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute intermittent porphyria
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute intermittent porphyria

Most Recent Events

  • 05 Jul 2012 Haem arginate licensed to Medunik in Canada
  • 07 Nov 2011 Registered for Acute intermittent porphyria in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top